Low Molecular Weight Heparin vs Direct Oral Anticoagulant... | NCT06913595

Studies
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

NCT06913595

Sponsor

Cairo University

Status

Active, not recruiting

Last Update Posted

Aug 26, 2025Actual

Enrollment

100Estimated

Phase

Phase 1

Conditions

Deep Venous Thrombosis

Interventions

Direct Oral Anticoagulant.
Low Molecular Weight Heparine

Countries

Egypt

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Aug 2025

Overall Recruitment Status or Expanded Access Status

Active, not recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Mar 25, 2024Actual

Primary Completion Date

Oct 25, 2025Estimated

Completion Date

Nov 1, 2025Estimated

First Submitted Date

Mar 24, 2025

First Submission Date that Met QC Criteria

Apr 3, 2025

First Posted Date

Apr 6, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Aug 23, 2025

Last Update Posted Date

Aug 26, 2025Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Detailed Description

This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

100Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Low Molecular Weight Heparin	Active Comparator	Low molecular weight heparin as aprophylaxis after bariatric surgery	Drug: Low Molecular Weight Heparine
Direct Oral Anticoagulant.	Experimental	Direct Oral Anticoagulant as aprophylaxis after bariatric surgery	Drug: Direct Oral Anticoagulant.

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Direct Oral Anticoagulant.	Drug	Direct Oral Anticoagulant AFTER BARIATRIC SURGERY	Direct Oral Anticoagulant.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
VENOUS THROMBOEMBOLISM	DVT after bariatric surgery	1 year

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

- BARIATRIC PATIENTS

Exclusion Criteria:

BLEEDING TENDENCY

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
mohammed elshwadfy	Cairo University	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Cairo University		Cairo		11511	Egypt

IPD Sharing Statement Module

Plan to Share IPD

Description

Not provided

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

Condition Browse Module

MeSH Terms

ID	Term
D020246	Venous Thrombosis

Ancestor Terms

ID	Term
D013927	Thrombosis
D016769	Embolism and Thrombosis
D014652	Vascular Diseases
D002318	Cardiovascular Diseases

Browse Leaves

Not provided

Browse Branches

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
C065145	N(4)-oleylcytosine arabinoside
D017984	Enoxaparin

Ancestor Terms

ID	Term
D006495	Heparin, Low-Molecular-Weight
D006493	Heparin
D006025	Glycosaminoglycans
D011134	Polysaccharides

Browse Leaves

Not provided

Browse Branches

Not provided